Adicet Bio reports Q1 net loss $28.2M ($0.31/sh); cash $150.4M; expects data readouts in 2H 2025

Adicet Bio, Inc.

2025-Q1 EPS reported -$0.31

Net loss $28.2M ($0.31 per share) vs $28.0M loss in Q1 2024; R&D spending $22.8M.
Cash $150.4M as of Mar 31, 2025; company expects to fund operations into 2H 2026.
Phase 1 trial of ADI-001 in autoimmune diseases expanded to LN/SLE; preliminary data expected 2H 2025.
Phase 1 trial of ADI-270 in metastatic/advanced ccRCC ongoing; preliminary data expected 2H 2025.
Michael Grissinger appointed to board; FDA granted Fast Track for ADI-001 in SLE and SSc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.